Lilly Xigris Indication For Low-Risk Sepsis Could Require Large Study

Lilly's Xigris efficacy assessment in low-risk sepsis patients would require a large trial population, FDA's Anti-Infective Drugs Advisory Committee suggested Oct. 16.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet